

Form PTO-1449 (modified)

Atty. Docket No.

UTSC:664USC1

Serial No.

10/672,763

List of Patents and Publications for Applicant's

Applicants

David Yang *et al.*

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Filing Date:

September 26, 2003

Group:

Unknown 1618

U.S. Patent Documents

See Page 1

Foreign Patent Documents

See Page 1

Other Art

See Page 1

## U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.
10	A1	2001/0041189	11/15/01	Xu	424	488	4/13/99
	A2	2001/0034363	10/25/01	Li <i>et al.</i>	514	449	3/30/98
	A3	4,418,068	11/29/83	Jones	424	267	12/16/81
	A4	4,507,466	3/26/85	Tomalia <i>et al.</i>	528	332	1/07/83
	A5	4,558,120	12/10/85	Tomalia <i>et al.</i>	528	363	12/27/83
	A6	4,568,737	2/04/86	Tomalia <i>et al.</i>	528	332	8/17/84
	A7	4,587,329	5/06/86	Tomalia <i>et al.</i>	528	363	7/19/85
	A8	4,631,337	12/23/86	Tomalia <i>et al.</i>	528	391	7/11/85
	A9	4,694,064	9/15/87	Tomalia <i>et al.</i>	528	332	2/28/86
	A10	4,713,975	12/22/87	Tomalia <i>et al.</i>	73	864.8	5/30/86
	A11	4,732,863	3/22/88	Tomasi <i>et al.</i>	436	547	12/31/84
	A12	4,737,550	4/12/88	Tomalia	525	419	12/08/86
	A13	4,857,599	8/15/89	Tomalia <i>et al.</i>	525	259	2/08/88
	A14	4,871,779	10/03/89	Killat <i>et al.</i>	521	28	12/23/85
	A15	4,988,496	01/29/91	Srinivasan <i>et al.</i>	424	1.1	05/31/88
	A16	5,087,616	2/11/92	Myers <i>et al.</i>	514	21	8/06/87
	A17	5,108,921	04/28/92	Low <i>et al.</i>	435	240.1	03/28/90
	A18	5,164,294	11/17/92	Skold <i>et al.</i>	435	7.5	7/07/89
	A19	5,279,811	1/18/94	Bergstein <i>et al.</i>	424	1.65	1/26/88
	A20	5,412,072	5/02/95	Sakurai <i>et al.</i>	530	322	3/21/90
	A21	5,416,016	05/16/95	Low <i>et al.</i>	435	240.1	03/13/92
	A22	5,517,993	5/21/96	Unger and Wu	128	653.4	6/07/95
	A23	5,534,241	7/09/96	Torchilin <i>et al.</i>	424	9.321	7/23/93

25356403.

EXAMINER:

DATE CONSIDERED: 5/31/05

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)

Form PTO-1449 (modified)		Atty. Docket No. UTSC:664USC1	Serial No. 10/672,763
List of Patents and Publications for Applicant's  INFORMATION DISCLOSURE STATEMENT  (Use several sheets if necessary)		Applicants David Yang <i>et al.</i>	
		Filing Date: September 26, 2003	Group: Unknown 1618
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 1</i>	Other Art <i>See Page 1</i>	

## U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.
	A24	5,605,671	2/25/97	Lyle <i>et al.</i>	424	1.41	4/29/94
	A25	5,635,382	06/03/97	Low <i>et al.</i>	435	172.3	12/05/94
	A26	5,635,603	6/03/97	Hansen <i>et al.</i>	530	391.5	12/05/94
	A27	5,670,132	9/23/97	Griffiths <i>et al.</i>	424	1.11	9/20/94
	A28	5,688,488	11/18/97	Low <i>et al.</i>	424	1.69	05/16/95
	A29	5,730,968	3/24/98	Butterfield <i>et al.</i>	424	78.37	3/31/94
	A30	5,820,847	10/13/98	Low <i>et al.</i>	424	9.1	01/15/97
	A31	5,830,431	11/03/98	Srinivasan <i>et al.</i>	424	1.69	6/07/95
	A32	5,908,777	6/01/99	Lee <i>et al.</i>	435	320.1	3/23/95
	A33	5,951,964	9/14/99	Dean <i>et al.</i>	424	1.69	6/4/93
	A34	5,955,053	9/21/99	Marzilli <i>et al.</i>	424	1.11	5/6/96
	A35	5,977,163	11/2/99	Li <i>et al.</i>	514	449	3/11/97
	A36	5,986,074	11/16/99	Marzilli <i>et al.</i>	534	14	12/18/97
	A37	6,071,533	6/06/00	Papahadjopoulos <i>et al.</i>	424	450	11/17/95
	A38	6,083,741	7/04/00	Hart <i>et al.</i>	435	320.1	11/17/95
	A39	6,113,946	9/05/00	Szoka, Jr. <i>et al.</i>	424	486	6/06/95
	A40	6,197,278	3/6/01	Blankenberg <i>et al.</i>	424	1.69	4/29/98
	A41	6,251,866	6/26/01	Prakash <i>et al.</i>	514	17	8/04/98
	A42	6,262,107	7/17/01	Li <i>et al.</i>	514	449	7/01/99

## Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No
	B1	WO 95/28966	11/02/95	PCT			

EXAMINER:

DATE CONSIDERED: 5/31/05

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)

Form PTO-1449 (modified)		Atty. Docket No. UTSC:664USC1	Serial No. 10/672,763
List of Patents and Publications for Applicant's  INFORMATION DISCLOSURE STATEMENT  (Use several sheets if necessary)		Applicants David Yang <i>et al.</i>	
		Filing Date: September 26, 2003	Group: Unknown <i>10/18</i>
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 1</i>	Other Art <i>See Page 1</i>	

## Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No
<i>[initials]</i>	B2	WO 97/33552	9/18/97	PCT	<i>[initials]</i>	<i>[initials]</i>	
<i>[initials]</i>	B3	WO 99/39748	8/12/99	PCT	<i>[initials]</i>	<i>[initials]</i>	
<i>[initials]</i>	B4	WO 99/49901	10/07/99	PCT	<i>[initials]</i>	<i>[initials]</i>	
<i>[initials]</i>	B5	WO 99/61512	12/02/99	PCT	<i>[initials]</i>	<i>[initials]</i>	
<i>[initials]</i>	B6	WO 00/53233	9/14/00	PCT	<i>[initials]</i>	<i>[initials]</i>	
<i>[initials]</i>	B7	WO 00/61788	10/19/00	PCT	<i>[initials]</i>	<i>[initials]</i>	

## Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
<i>[initials]</i>	C1	Abrams <i>et al.</i> , "Technetium-99m-human polyclonal IgG radiolabeled via the hydrazino nicotinamide derivative for imaging focal sites of infection in rats," <i>J. Nucl. Med.</i> , 31:2022-2028, 1990.
<i>[initials]</i>	C2	Alper <i>et al.</i> , "Assessment of renal functional changes following transurethral prostatectomy using tc-99m ethylenedicycysteine," <i>J. Nuclear Med.</i> , 37:289P, Abstract No. 1292, 1996.
<i>[initials]</i>	C3	Anderson <i>et al.</i> , "N,N'-ethylene-di-l-cysteine (ec) complexes of ga(III) and In (III): molecular modeling, thermodynamic stability and in vivo studies," <i>Nucl. Med. Biol.</i> , 22:165-173, 1995.
<i>[initials]</i>	C4	Anderson <i>et al.</i> , "Radiometal-labeled agents (non-technetium) for diagnostic imaging," <i>Chem. Rev.</i> , 99:2219-2234, 1999.
<i>[initials]</i>	C5	Antony, "Folate receptors," <i>Ann. Rev.</i> , 16:501-521, 1996.
<i>[initials]</i>	C6	Aoi <i>et al.</i> , "Globular carbohydrate macromolecule 'sugar balls' 3. 'radical-growth polymerization' of sugar-substituted $\alpha$ -amino acid N-carboxyanhydrides (glycoNCAs) with a dendritic initiator," <i>Tetrahedron, Elsevier Science Publishers</i> , 53(45):15415-15427, 1997.
<i>[initials]</i>	C7	Baidoo and Lever, "Evaluation of a diaminedithiol-based bifunctional chelate for labeling small molecules with $^{99m}\text{Tc}$ ," <i>Technetium and Rhenium in Chemistry and Nuclear Medicine</i> , 1990.
<i>[initials]</i>	C8	Baidoo <i>et al.</i> , "Synthesis of a new diaminedithiol bifunctional chelate for the preparation of neutral technetium complexes," <i>J. Nuclear Med.</i> , 31:806, Abstract No. 414, 1990.

25356403J

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No. UTSC:664USC1	Serial No. 10/672,763
List of Patents and Publications for Applicant's  INFORMATION DISCLOSURE STATEMENT  (Use several sheets if necessary)		Applicants David Yang <i>et al.</i>	
		Filing Date: September 26, 2003	Group: Unknown 1618
U.S. Patent Documents See Page 1	Foreign Patent Documents See Page 1	Other Art See Page 1	

### Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C9	Bajorin <i>et al.</i> , <i>Proc. Annu. Meet. Am. Soc. Clin. Oncol.</i> , 7:250, A967, 1988.
	C10	Bakker <i>et al.</i> , "Receptor scintigraphy with a radioiodinated somatostatin analogue: radiolabeling, purification, biologic activity and in vivo application in animals," <i>J. Nucl. Med.</i> , 31:1501-1509, 1990.
	C11	Bar-Sever <i>et al.</i> , "Comparison of living related donor and recipient renograms in predicting the early postransplantation course," <i>J. Nuclear Med.</i> , 37:292P, Abstract No. 1305, 1996.
	C12	Baselga <i>et al.</i> , "Phase I studies of anti-epidermal growth factor receptor cheimeric antibody C225 alone and in combination with cisplatin," <i>J. Clinical Oncology</i> , 18(4):904-914, 2000.
	C13	Baselga <i>et al.</i> , "Recombinant humanized anti-HER2 antibody (herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/new overexpressing human breast cancer xenografts," <i>Cancer Research</i> , 58:2825-2831, 1998.
	C14	Becker <i>et al.</i> , "Analysis of E-cadherin in diffuse-type gastric cancer using a mutation-specific monoclonal antibody," <i>American Journal of Pathology</i> , 155(6):1803-1809.
	C15	Benns <i>et al.</i> , "Tailoring new gene delivery designs for specific targets," <i>Journal of Drug Targeting</i> , 8(1), Database Medline on STN International, Accession No. 2000222278, 2 pages, 2000.
	C16	Blackenberg <i>et al.</i> , "Apoptosis: the importance of nuclear medicine," <i>Nucl. Med. Comm.</i> , 21:241-250, 2000.
	C17	Blackenberg <i>et al.</i> , "In vivo detection and imaging of phosphatidylserine expression during programmed cell death," <i>Proc. Natl. Acad. Sci., USA</i> , 95:6349-6354, 1998.
	C18	Blair <i>et al.</i> , "Linkage of cytotoxin agents to immunoglobulins," <i>Journal of Immunological Methods</i> , 59:129-143, 1983.
	C19	Blakenberg <i>et al.</i> , "Imaging of apoptosis (programmed cell death) with <sup>99m</sup> Tc annexin V," <i>J. Nucl. Med.</i> , 40:184-191, 1999.
	C20	Block, "Poly(g-benzyl-L-glutamate) and other glutamic acid containing polymers," Gordon and Breach Science Publishers, New York, 11-31, 1983.
	C21	Blondeau <i>et al.</i> , "Dimerization of an intermediate during the sodium in liquid ammonia reduction of L-thiazolidine-4-carboxylic acid," <i>Can J. Chem.</i> , 45:49-52, 1967.

25356403.1

EXAMINER:



DATE CONSIDERED 5/31/07

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)

Form PTO-1449 (modified)		Atty. Docket No. UTSC:664USC1	Serial No. 10/672,763
List of Patents and Publications for Applicant's  INFORMATION DISCLOSURE STATEMENT  (Use several sheets if necessary)		Applicants David Yang <i>et al.</i>	
		Filing Date: September 26, 2003	Group: Unknown 1618
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 1</i>	Other Art <i>See Page 1</i>	

### Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C22	Bohdiewicz <i>et al.</i> , "Indium-111 satumomab pendetide: the first FDA-approved monoclonal antibody for tumor imaging," <i>J. Nuclear Medicine Technology</i> , 26(3):155-163, 1998.
	C23	Brechbiel <i>et al.</i> , "Synthesis of 1 (P-isothiocyanatobenzyl) derivatives of DTPA and EDTA: antibody labeling and tumor-imaging studies," <i>Inorg. Chem.</i> , 25:2772-2781, 1986.
	C24	Brogi <i>et al.</i> , "Hypoxia-induced paracrine regulation of vascular endothelial growth factor receptor expression," <i>J. Clin. Invest.</i> , 97(2):469-476, 1996.
	C25	Brokx <i>et al.</i> , "Designing peptide-based scaffolds as drug delivery vehicles," <i>Science</i> , 78(1-3):115-123, 2002.
	C26	Budihardjo <i>et al.</i> , "Biochemical pathways of caspase activation during apoptosis," <i>Annu. Rev. Cell Dev. Biol.</i> , 15:269-290, 1999.
	C27	Burgen, "Targets of drug action," <i>Ann. Rev. Pharmacol. Toxicol.</i> , 40:1-16, 2000.
	C28	Bush <i>et al.</i> , "Definitive evidence for hypoxic cells influencing cure in cancer therapy," <i>Br J Cancer</i> , (Suppl. III) 37:302-306, 1978.
	C29	Campbell <i>et al.</i> , "Folate-binding protein is a marker for ovarian cancer," <i>Cancer Res</i> , 51:5329-5338, 1991.
	C30	Chapman <i>et al.</i> , "Therapeutic antibody fragments with prolonged in vivo half-lives," <i>Nature Biotech.</i> , 17:780-783, 1999.
	C31	Chen <i>et al.</i> , "Biological and pharmacokinetic evaluation of tc-99m ma2g2-b: a potential renal agent," <i>J. Nuclear Med.</i> , 35:263P, Abstract No. 1082, 1994.
	C32	Cherif <i>et al.</i> , "Rapid synthesis of [ <sup>18</sup> F]Fluoro-1-(2'-Nitro-1'-Imidazolyl)-2-Propanol ([ <sup>18</sup> F]Fluoromisonidazole)," <i>Pharm Res.</i> , 11:466-469, 1994.
	C33	Cleynhens <i>et al.</i> , "Synthesis and biological evaluation in mice of a monoamide derivative of tc-99m-l, l-ec," <i>J. Nuclear Med.</i> , 38:186P, Abstract No. 799, 1997.
	C34	Collier <i>et al.</i> , "Immunoscintigraphy performed with In-111-labeled CYT-103 in the management of colorectal cancer: comparison with CT," <i>Radiology</i> , 185:179-186, 1992.
	C35	Coney <i>et al.</i> , "Chimeric murine-human antibodies directed against folate binding receptor are efficient mediators of ovarian carcinoma cell killing," <i>Cancer Res</i> , 54:2448-2455, 1994.

25356403.1

EXAMINER: 

DATE CONSIDERED: 5/31/05

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No. UTSC:664USC1	Serial No. 10/672,763
List of Patents and Publications for Applicant's  INFORMATION DISCLOSURE STATEMENT  (Use several sheets if necessary)		Applicants David Yang <i>et al.</i>	
		Filing Date: September 26, 2003	Group: Unknown 1618
U.S. Patent Documents See Page 1	Foreign Patent Documents See Page 1	Other Art See Page 1	

### Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C36	Corlija <i>et al.</i> , "Contribution of radiolytically induced dissociation of 99mtc-d,1-hmpao in aqueous solutions," <i>J. Nuclear Med.</i> , 31:806, Abstract No. 413, 1990.
	C37	Craig <i>et al.</i> , "Renal outcomes for children on year after urinary tract infection," <i>J. Nuclear Med.</i> , 37:46P, Abstract No. 175, 1996.
	C38	Culver <i>et al.</i> , "In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors," <i>Science</i> , 256:1550-1552, 1992.
	C39	Dagli <i>et al.</i> , "Analysis of the complete dynamic scan data for camera-based determination of renal function," <i>J. Nuclear Med.</i> , 37:91P, Abstract No. 354, 1996.
	C40	Davison <i>et al.</i> , "A new class of oxotechnetium(5+) chelate complexes containing a TcON <sub>2</sub> S <sub>2</sub> Core," <i>Inorg Chem</i> , 20:1629-1632, 1981.
	C41	de Klerk <i>et al.</i> , "Aspirin versus captopril renography in the diagnosis of renal artery stenosis," <i>J. Nuclear Med.</i> , 37:289P, Abstract No. 1291, 1996.
	C42	Deguchi <i>et al.</i> , "Retention of biologic activity of human epidermal growth factor following conjugation to a blood-brain barrier drug delivery vector via an extended poly(ethylene glycol) linker," <i>Bioconjugate Chem.</i> , 10:32-37, 1999.
	C43	DeNardo <i>et al.</i> , "Pharmacokinetics of chimeric L6 conjugated to indium 111- and yttrium-90-DOTA-peptide in tumor-bearing mice," <i>J. Nuclear Medicine</i> , 36:829-836, 1995.
	C44	DeNardo <i>et al.</i> , "Yttrium-90/indium-111-DOTA-peptide-chimeric L6: Pharmacokinetics, dosimetry and initial results in patients with incurable breast cancer," <i>Anticancer Research</i> , 17(3B):1735-1744, 1997.
	C45	Deutsch <i>et al.</i> , "Synthesis of congeners and prodrugs, water-soluble prodrugs of taxol with potent antitumor activity," <i>J. Med. Chem.</i> , 32:788-792, 1989.
	C46	Dewanjee <i>et al.</i> , "Labeling antisense oligodeoxynucleotide (on) with tc-99m and hybridization with c-myc oncogene mrna in p388 leukemic cells," <i>J. Nuclear Med.</i> , 35:263P, Abstract No. 1081, 1994.
	C47	Dezutter <i>et al.</i> , "Preparation and biological evaluation of technetium- <sup>99m</sup> -L,L-propylenedicysteine" <i>J. of Labelled Cpd. Radiopharm.</i> , 42:553-565, 1999.
	C48	Dische, "A review of hypoxic-cell radiosensitization," <i>Int J Radiat Oncol Biol Phys</i> , 20:147-152, 1991.

25356403.1



EXAMINER:

DATE CONSIDERED: 5/31/05

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No. UTSC:664USC1	Serial No. 10/672,763
List of Patents and Publications for Applicant's  INFORMATION DISCLOSURE STATEMENT  (Use several sheets if necessary)		Applicants David Yang <i>et al.</i>	
		Filing Date: September 26, 2003	Group: Unknown 1618
U.S. Patent Documents See Page 1	Foreign Patent Documents See Page 1	Other Art See Page 1	

### Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C49	Divgi <i>et al.</i> , "Phase I and imaging trial of indium 111-labeled anti-epidermal growth factor receptor monoclonal antibody 225 in patients with squamous cell lung carcinoma," <i>J. National Cancer Institute</i> , 83(2):97-104, 1991.
	C50	Drobnik <i>et al.</i> , "Soluble synthetic polymers in biological systems," <i>Adv. Polym. Sci.</i> , 57:1-50, 1984.
	C51	Dunn <i>et al.</i> , "Receptor-mediated endocytosis of epidermal growth factor by hepatocytes in the perfused rat liver: ligand and receptor dynamics," <i>J. Cell Biol.</i> , 98:2148-2159, 1984.
	C52	Eary <i>et al.</i> , "Radiochemistry of halogenated antibodies," <i>Antibodies in Radiodiagnosis and Therapy</i> , Boca Raton, Florida, CPC Press, 83-100, 1988.
	C53	Eiseman <i>et al.</i> , "Plasma pharmacokinetics and tissue distribution of paclitaxel in CD2F1 mice," <i>Cancer Chemother. Pharmacol.</i> , 34:465-471, 1994.
	C54	Eisenhut <i>et al.</i> , "Synthesis and <i>In Vivo</i> Testing of a bromobutyl substituted 1,2-Dithia-5,9-diazacycloundecane: a versatile precursor for new <sup>99m</sup> Tc-bis(aminoethanethiol) complexes," <i>Nucl. Med. Biol.</i> , 16:805-811, 1989.
	C55	Ennis <i>et al.</i> , "Anti-epidermal growth factor receptor antibodies inhibit the autocrine-stimulated growth of MDA-468 human breast cancer cells," <i>Mol. Endocrinology</i> , 3(11):1830-1838, 1989.
	C56	Eshima <i>et al.</i> , "Evaluating the role of protein binding on the renal extraction of tc-99m tubular agents utilizing an isolated perfused rat kidney model," <i>J. Nuclear Med.</i> , 37:47P, Abstract No. 178, 1996.
	C57	Ethier, "Growth factor synthesis and human breast cancer progression," <i>J. Natl. Cancer Inst.</i> , 87(13):964-973, 1995.
	C58	Fan <i>et al.</i> , "Antitumor effect of anti-epidermal growth factor receptor monoclonal antibodies plus cis-diamminedichloroplatinum on well established A431 cell xenografts," <i>Cancer Research</i> , 53:4637-4642, 1993.
	C59	Fan <i>et al.</i> , "Blockade of epidermal growth factor receptor function by bivalent and monovalent fragments of 225 anti-epidermal growth factor receptor monoclonal antibodies," <i>Cancer Research</i> , 53:4322-4328, 1993.
	C60	Fanciulli <i>et al.</i> , "Glycolysis and growth rate in normal and in hexokinase-transfected NIH-3T3 cells," <i>Oncology Res.</i> , 6:405-409, 1994.

25356403.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No. UTSC:664USC1	Serial No. 10/672,763
List of Patents and Publications for Applicant's  INFORMATION DISCLOSURE STATEMENT  (Use several sheets if necessary)		Applicants David Yang <i>et al.</i>	
		Filing Date: September 26, 2003	Group: Unknown <i>11618</i>
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 1</i>	Other Art <i>See Page 1</i>	

### Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
<i>[Signature]</i>	C61	Fang <i>et al.</i> , "Involvement of p21 Waf1 in mediating inhibition of paclitaxel-induced apoptosis by epidermal growth factor in MDA-MB-468 human breast cancer cells," <i>Anticancer Research</i> , 20(1A):103-112, 2000.
	C62	Fidler <i>et al.</i> , "The biology of cancer invasion and metastasis," <i>Adv. Cancer Res.</i> , 28:149-250, 1987.
	C63	Foa <i>et al.</i> , "Taxol (paclitaxel): a novel anti-microtubule agent with remarkable anti-neoplastic activity," <i>J. Clin. Lab. Res.</i> , 24:6-14, 1994.
	C64	Frankel <i>et al.</i> , "Targeted toxins," <i>Clin. Cancer Res.</i> , 6:326-334, 2000.
	C65	Franklin <i>et al.</i> , "New anti-lung-cancer antibody cluster 12 reacts with human folate receptors present on adenocarcinoma," <i>Int J Cancer-Supplement</i> , 8:89-95, 1994.
	C66	Fuertges <i>et al.</i> , "The clinical efficacy of poly(ethylene glycol)-modified porceins," <i>J. Controlled Release</i> , 11:139-148, 1990.
	C67	Fuller <i>et al.</i> , "A procedure for the facile synthesis of amino-acid N-carboxyanhydride," <i>Biopolymers</i> , 15:1869, 1976.
	C68	Gabizon, "Selective tumor localization and improved therapeutic index of anthracyclines encapsulated in long-circulating liposomes," <i>Cancer Research</i> , 52:891-896, 1992.
	C69	Garayoa <i>et al.</i> , "Hypoxia-inducible factor-1 (HIF-1) up-regulates adrenomedullin expression in human tumor cell lines during oxygen deprivation: a possible promotion mechanism of carcinogenesis," <i>Molecular Endocrinology</i> , 14:848-862, 2000.
	C70	Garipey <i>et al.</i> , "Vectorial delivery of macromolecules into cells using peptide-based vehicles," <i>Trends in Biotechnology</i> , 19(1):21-28, 2001.
<i>[Signature]</i>	C71	Girard, "Mechanisms by which carbohydrates regulate expression genes for clycolytic and lipogenic enzymes," <i>Ann. Rev. Nutr.</i> , 17:325-352, 1997.
	C72	Giraud <i>et al.</i> , "Application to a cartilage targeting strategy: Synthesis and in vivo biodistribution of <sup>14</sup> C-labelled quaternary ammonium-glucosamine conjugates," <i>Bioconjug. Chem.</i> , 11:212-218, 2000.
<i>[Signature]</i>	C73	Goh <i>et al.</i> , "Growth hormone promotion of tubulin polymerization stabilizes the microtubule network and protects against colchicine-induced apoptosis," <i>Endocrinology</i> , 139:4364-4372, 1998.

25356403.1

EXAMINER:


DATE CONSIDERED: *5/31/05*

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPE §609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.



Form PTO-1449 (modified)		Atty. Docket No. UTSC:664USC1	Serial No. 10/672,763
List of Patents and Publications for Applicant's  INFORMATION DISCLOSURE STATEMENT  (Use several sheets if necessary)		Applicants David Yang <i>et al.</i>	
		Filing Date: September 26, 2003	Group: Unknown 1668
U.S. Patent Documents See Page 1	Foreign Patent Documents See Page 1	Other Art See Page 1	

### Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C74	Goldenberg <i>et al.</i> , "Imaging of human tumor xenografts with and indim-111-labeled anti-epidermal growth factor receptor monoclonal antibody," <i>J. National Cancer Institute</i> , 81:1616-1625, 1989.
	C75	Goldenberg, "Monoclonal antibodies in cancer detection and therapy," <i>Am. J. Med.</i> , 94:297-312, 1993.
	C76	Goldsmith <i>et al.</i> , "Somatostatin receptor imaging in lymphoma," <i>Sem Nucl Med</i> , 25:262-271, 1995.
	C77	Goldsmith, "Receptor imaging: Competitive or complementary to antibody imaging," <i>Sem Nucl Med.</i> , 27:85-93, 1997.
	C78	Goldspeil, "Pharmaceutical issues: preparation, administration, stability, and compatibility othw other medications," <i>Ann. Pharocother.</i> , 28:S23-S26, 1994.
	C79	Gonda, "Aerosols for delivery of therapeutic and diagnostic agents to the respiratory tract," <i>Critical Reviews in Therapeutic Drug Carrier Systems</i> , 6(4):273-313, 1990.
	C80	Greenfield <i>et al.</i> , "In vitro evaluation of immunoconjugates prepared by linking mitomycin C to monoclonal antibodies via polyglutamic acid carriers," <i>Antibody, Immunoconjugates, and Radiopharmaceuticals</i> , 2(3):201-216, 1989.
	C81	Greenwald <i>et al.</i> , "Drug delivery systems: water soluble tazol 2'-poly(ethylene glycol) ester prodrugs-design and in vivo effectiveness," <i>J. Med. Chem.</i> , 39:424-431, 1996.
	C82	Guozheng and Boli, "A new potential renal imaging agent 99mtcn-ec," <i>J. Labelled compounds and Radiopharmaceuticals</i> , XXXVII:797-798, 1995.
	C83	Hadley <i>et al.</i> , "Magnetic resonance imaging in acute head injury," <i>Clin. Rad.</i> , 39:131-139, 1988.
	C84	Halpern <i>et al.</i> , "Stability, characterization, and kinetics of In-labeled monoclonal antitumor antibodies in normal animals and nude mouse human tumor models," <i>Cancer Research</i> , 43:5347-5355, 1983.
	C85	Harada <i>et al.</i> , "Insulin-induced egr-1 expression in chinese hamster ovary cells in insulin receptor an dinsulin receptor substrate-1 phosphorylation-independent," <i>J. Biol Chem.</i> , 270:26632-26638, 1995.

25356403.1

EXAMINER:

DATE CONSIDERED: 5/24/07

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No. UTSC:664USC1	Serial No. 10/672,763
List of Patents and Publications for Applicant's  INFORMATION DISCLOSURE STATEMENT  (Use several sheets if necessary)		Applicants David Yang <i>et al.</i>	
		Filing Date: September 26, 2003	Group: Unknown 1618
U.S. Patent Documents See Page 1	Foreign Patent Documents See Page 1	Other Art See Page 1	

### Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C86	Hay <i>et al.</i> , "Hypoxia-selective antitumor agents. Bis(nitroimidazolyl)alkanecarboxamides: a new class of hypoxia-selective cytotoxins and hypoxic cell radiosensitizers," <i>J Med. Chem.</i> , 37:381-391, 1994.
	C87	Hermann and Patel, "Adaptive recognition by nucleic acid aptamers," <i>Science</i> , 287:820-825, 2000.
	C88	Hermanson, "Amine detection reagents," <i>Bioconjugate Techniques</i> , San Diego, Academic Press, 112-114, 1996.
	C89	Hermanson, "Ellman's assay for the determination of sulfhydryls," <i>Bioconjugate Techniques</i> , Sand Diego, Academic Press, 88-90, 1996.
	C90	Hibi <i>et al.</i> , "PGP9.5 as a candidate tumor marker for non-small-cell lung cancer," <i>American Journal of Pathology</i> , 155(3):711-715, 1999.
	C91	Hnatowich <i>et al.</i> , "Radioactive labeling of antibody: a simple and efficient method," <i>Science</i> , 220:613-615, 1983.
	C92	Hoes <i>et al.</i> , "Optimization of macromolecular prodrugs of the antitumor antibiotic adriamycin," <i>J. Controlled Release</i> , 2:205-213, 1985.
	C93	Holm <i>et al.</i> , "Folate receptor of human mammary adenocarcinoma," <i>APMIS</i> , 102:413-419, 1994.
	C94	Holmes <i>et al.</i> , "Current status oc clinical trials with paclitaxel and docetael, taxane anticancer agents: basic science and current status," <i>American Chemical Society</i> , Washington, DC, 31-57, 1995.
	C95	Hsueh and Dolnick, "Altered folate-binding protein mRNA stability in KB cells grown in folate-deficient medium," <i>Biochem Pharmacol</i> , 45:2537-2545, 1993.
	C96	Hudecz <i>et al.</i> , "Influence of carrier on biodistribution and in vitro cytotoxicity of methotexate-branched polypeptide conjugates," <i>Bioconjugate Chemistry</i> , American Chemical Society, 4(1):25-33, 1993.
	C97	Ilgan <i>et al.</i> , " <sup>99m</sup> Tc-ethylenedicysteine-folate: a new tumor imaging agent, synthesis, labeling and evaluation in animals," <i>Cancer Biotherapy &amp; Radiopharmaceuticals</i> , 13:427-435, 1998.

25356403.1

EXAMINER:




DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)

Form PTO-1449 (modified)		Atty. Docket No. UTSC:664USC1	Serial No. 10/672,763
List of Patents and Publications for Applicant's  INFORMATION DISCLOSURE STATEMENT  (Use several sheets if necessary)		Applicants David Yang <i>et al.</i>	
		Filing Date: September 26, 2003	Group: Unknown 1668
U.S. Patent Documents See Page 1	Foreign Patent Documents See Page 1	Other Art See Page 1	

### Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C98	Inoue <i>et al.</i> , "Paclitaxel enhances the effects of the anti-epidermal growth factor receptor monoclonal antibody ImClone C225 in mice with metastatic human bladder transitional cell carcinoma," <i>Clinical Cancer Res.</i> , 6:4874, 4884, 2000.
	C99	Irie <i>et al.</i> , "Regression of cutaneous metastatic melanoma by intralesional injection with human monoclonal antibody to ganglioside GD2," <i>Proc. Natl. Acad. Sci., USA</i> , 83:8694-8698, 1986.
	C100	Itoh <i>et al.</i> , "Graphic (patlak) method in tc-99m-mag3 renal scintigraphy: noninvasive calculation of extraction fraction (ef) and renal plasma flow (RPF)," <i>J. Nuclear Med.</i> , 37:291P, Abstract No. 1300, 1996.
	C101	Jamar <i>et al.</i> , "Clearance of the new tubular agent Tc-99m L,L-ethylenedicycysteine: Estimation by a simplified method," <i>J Nucl Med</i> , 34:129P, 1993.
	C102	Jeppesen <i>et al.</i> , "Impact of polymer tether length on multiple ligand-receptor bond formation," <i>Science</i> , 293:465-468, 2001.
	C103	John <i>et al.</i> , "Tc-99m labeled ethylenediamines: quest for sigma receptor chelates," <i>J. Nuclear Med.</i> , 38:186P, Abstract No. 798, 1997.
	C104	Jones and Mayer, "Glucose metabolism in the rat small intestine: the effect of glucose analogues on hexokinase activity," <i>Biochem. J.</i> , 132:125-128, 1973.
	C105	Jurisson <i>et al.</i> , "Potential technetium small molecule radiopharmaceuticals," <i>Chem. Rev.</i> , 99:2205-2218, 1999.
	C106	Kabasakal <i>et al.</i> , "Clinical comparison of technetium- <sup>99m</sup> -ec, technetium- <sup>99m</sup> -MAG3 and iodine-131-OIH in renal disorders," <i>J. Nucl. Med.</i> , 36(2):224-228, 1995.
	C107	Kabasakal <i>et al.</i> , "Evaluation of technetium-99m-ethylenedicycysteine in renal disorders and determination of extraction ratio," <i>J. Nucl. Med.</i> , 36(8):1398-1403, 1995.
	C108	Kabasakal <i>et al.</i> , "Prospective validation of single plasma sample <sup>99m</sup> Tc-ethylenedicycysteine clearance in adults," <i>J. Nucl. Med.</i> , 40:429-431, 1999.
	C109	Kabasakal <i>et al.</i> , "Simplified technetium- <sup>99m</sup> -EC clearance in adults from a single plasma sample," <i>J. Nuclear Med.</i> , 38:1784-1786, 1997.
	C110	Kabasakal. "Technetium-99m ethylene dicycysteine: a new renal tubular function agent," <i>Eur. J Nucl. Med.</i> 27:351-357, 2000.

25356403.1

EXAMINER: 

DATE CONSIDERED: 5/31/05

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No. UTSC:664USC1	Serial No. 10/672,763
List of Patents and Publications for Applicant's  INFORMATION DISCLOSURE STATEMENT  (Use several sheets if necessary)		Applicants David Yang <i>et al.</i>	
		Filing Date: September 26, 2003	Group: Unknown <i>11/18</i>
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 1</i>	Other Art <i>See Page 1</i>	

### Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
<i>10/18</i>	C111	Kanazawa <i>et al.</i> , "19F NMR of 2-deoxy-2-fluoro-D-glucos for tumor diagnosis in mice. An NDP-bound hexose analog as a new NMR target for imaging," <i>NMR in Biomed.</i> , 10:35-41, 1997.
	C112	Kanvinde <i>et al.</i> , "Technetium-99m-γ-pyrones: a new class of tc-99m cationic complexes," <i>J. Nuclear Medicine</i> , 31:908, Abstract, 1990.
	C113	Kao <i>et al.</i> , "Role of radioisotope penile plethysmography in the evaluation of penile hemodynamic of impotent patients," <i>J. Nuclear Med.</i> , 37:292P, Abstract No. 1304, 1996.
	C114	Kato and Sugiyama, "Targeted delivery of peptides, proteins, and genes by receptor-mediated endocytosis," <i>Critical Reviews in Therapeutic Drug Carrier Systems</i> , 14(3):287-331, 1997.
	C115	Kato <i>et al.</i> , "A novel method of conjugation of daunomycin with antibody with a poly-L-glutamic acid-α-fetoprotein antibody-daunomycin conjugate," <i>J. Med. Chem.</i> , 27:1602-1607, 1984.
	C116	Kengen, "Good results of tc-99m-mag3 clearance measurements with a dual headed gamma camera without plasma sampler," <i>J. Nuclear Med.</i> , 37:91P, Abstract No. 353, 1996.
	C117	Kikukawa <i>et al.</i> , "Early and delayed Tc-99m ECD brain SPECT in SLE patients with CNS involvement," <i>Ann Nucl Med.</i> 14:25-32, 2000.
	C118	Kim <i>et al.</i> , "Synthesis, biodistribution and imaging of mammary tumors using 99mTc-ec-polyglutamate; a glutamate receptor peptide," <i>J. Nuclear Medicine</i> , 41:231P Abstract, 2000.
	C119	Kitamura <i>et al.</i> , "Chemical engineering of the monoclonal antibody A7 by polyethylene glycol for targeting cancer chemotherapy," <i>Cancer Research</i> , 51:4310-4315, 1991.
	C120	Klok <i>et al.</i> , "Star-shaped fluorescent polypeptides," <i>Journal of Polymer Science</i> , 39(10):1572-1582, 2001.
<i>10/18</i>	C121	Knight <i>et al.</i> , "Thrombus imaging with technetium-99m synthetic peptides based upon the binding domain of a monoclonal antibody to activated platelets," <i>J. Nucl. Med.</i> , 35:282-288, 1991.
	C122	Koh <i>et al.</i> , "Imaging of hypoxia in human tumors with [F-18]fluoromisonidazole," <i>Int J Radiat Oncol Biol Phys</i> , 22:199-212, 1992.
<i>10/18</i>	C123	Kopecek <i>et al.</i> , "Targetable polymeric prodrugs," <i>J. Control. Release</i> , 6:315-327, 1987.

25356403.1

EXAMINER: *[Signature]*DATE CONSIDERED: *5/21/07*

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)

Form PTO-1449 (modified)		Atty. Docket No. UTSC:664USC1	Serial No. 10/672,763
List of Patents and Publications for Applicant's  INFORMATION DISCLOSURE STATEMENT  (Use several sheets if necessary)		Applicants David Yang <i>et al.</i>	
		Filing Date: September 26, 2003	Group: Unknown <i>Welsh</i>
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 1</i>	Other Art <i>See Page 1</i>	

### Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C124	Kopecek <i>et al.</i> , "Targetable water-soluble polymeric anticancer drugs: achievements and unsolved problems," <i>Proc. Intern. Symp. Conol. Rel. Bioact. Mater.</i> , 20:190-191, 1993.
	C125	Kopecek, "The potential of water-soluble polymeric carriers in targeted and site-specific drug delivery," <i>Journal of Controlled Release</i> , 11:279-290, 1990.
	C126	Kranz <i>et al.</i> , "Conjugates of folate and anti-T-cell-receptor antibodies specifically target folate-receptor-positive tumor cells for lysis," <i>Proc Natl Acad Sci</i> , 92:9057-9061, 1995.
	C127	Lamberts <i>et al.</i> , "Somatostatin receptor imaging in vivo localization of tumors with a radiolabeled somatostatin analog," <i>J. Steroid Biochem Mol Biol</i> , 37:1079-1082, 1990.
	C128	Lamki, "Radioimmunoscinigraphy of cancer: problems, pitfalls, and prospects," <i>Nuclear Medicine Annual 1990</i> , New York, Raven Press Ltd., 113-150, 1990.
	C129	Larson <i>et al.</i> , "Overview of clinical radioimmunodetection of human tumors," <i>Cancer</i> , 73(supp):832-835, 1994.
	C130	Leamon and Low, "Cytotoxicity of momordin-folate conjugates in cultured human cells," <i>J Biol Chem</i> , 267:24966-24971, 1992.
	C131	Leamon and Low, "Delivery of macromolecules into living cells: a method that exploits folate receptor endocytosis," <i>Proc Natl Acad Sci</i> , 88:5572-5576, 1991.
	C132	Leamon <i>et al.</i> , "Cytotoxicity of folate-pseudomonas exotoxin conjugates toward tumor cells," <i>J Biol Chem</i> , 268:24847-24854, 1993.
	C133	Lee and Low, "Delivery of liposomes into cultured KB cells via folate receptor-mediated endocytosis," <i>J Biol Chem</i> , 269:3198-3204, 1994.
	C134	Lees <i>et al.</i> , "Prognostic value of single-photon emission tomography in acute ischaemic stroke," <i>Eur. Journ. Nuc. Med.</i> , 24:21-26, 1989.
	C135	Li <i>et al.</i> , "Antitumor activity of poly (L-glutamic acid)-paclitaxel on syngeneic and xenograft tumors," <i>Clinical Cancer Res.</i> , 5:891-897, 1999.
	C136	Li <i>et al.</i> , "Complete regression of well-established tumors using a novel water-soluble poly(L-glutamic acid)-paclitaxel conjugate," <i>Cancer Res.</i> , 58:2404-2409, 1998.
	C137	Li <i>et al.</i> , "Poly(L-glutamic acid)-anticancer drug conjugates," <i>Advanced Drug Delivery Rev.</i> , 54:695-713, 2002.

25356403.1

EXAMINER:

DATE CONSIDERED: *5/31/05*

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No. UTSC:664USC1	Serial No. 10/672,763
List of Patents and Publications for Applicant's  INFORMATION DISCLOSURE STATEMENT  (Use several sheets if necessary)		Applicants David Yang <i>et al.</i>	
		Filing Date: September 26, 2003	Group: Unknown <i>1608</i>
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 1</i>	Other Art <i>See Page 1</i>	

### Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
<i>[Signature]</i>	C138	Li <i>et al.</i> , "Synthesis and evaluation of water-soluble polyethylene glycol paclitaxel conjugate as a paclitaxel prodrug," <i>Anticancer Drugs</i> , 7(5):642-648, 1996.
	C139	Li <i>et al.</i> , "Synthesis, metal chelate stability studies, and enzyme digestion of a peptide-linked DOTA derivative and its corresponding radiolabeled immunoconjugates," <i>Bioconjugate Chem.</i> , 4:275-283, 1993.
	C140	Liang <i>et al.</i> , "The use of diaminodithiol for labeling small molecules with technetium-99m," <i>Nucl. Med. Biol.</i> , 14:63-67, 1987.
	C141	Liu <i>et al.</i> , "99mTc-labeled small peptides as diagnostic radiopharmaceuticals," <i>Chem. Rev.</i> , 99:2235-2268, 1999.
	C142	Liu <i>et al.</i> , "Bifunctional chelators for therapeutic lanthanide radiopharmaceuticals," <i>Bioconjugate Chemistry</i> , 12:7-34, 2001.
	C143	Liu <i>et al.</i> , "Induction of apoptosis and activation of the caspase cascade by anti-EGF receptor monoclonal antibodies in DiFI human colon cancer cells do not involve the C-jun N-terminal kinase activity," <i>British Journal of Cancer</i> , 82(12):1991-1999, 2000.
	C144	Lu <i>et al.</i> , "Polymerizable fab' antibody fragments for targeting of anticancer drugs," <i>Nat. Biotech.</i> , 17:1101-1104, 1999.
	C145	Lu, "Antimitotic agents," In: Foye, WO. Ed., "Cancer chemotherapeutic agents," Washington, DC: American Chemical Society, 345-368, 1995.
	C146	Maeda <i>et al.</i> , "Tumorigenic and lymphotropic principles of macromolecular drugs," <i>Crit. Rev. Ther. Drug Carrier Syst.</i> , 6(3):193-210, 1989.
	C147	Maeda, "SMANCS and polymer-conjugated macromolecular drugs: advantages in cancer chemotherapy," <i>Adv. Drug Delivery Rev.</i> , 6(2):181-202, 1991.
	C148	Mangera and Verbruggen, "Synthesis and evaluation of .beta.-homocysteine derivatives of 99mTc-L, L-EC and 99mTc-L, L-ECD," <i>J. Labelled Comp. Radiopharm.</i> , 42:683-699, 1999.
	C149	Mann <i>et al.</i> , "Molecular amplifiers: synthesis and functionalization of a poly(aminopropyl dextran bearing a uniquely reactive terminus for univalent attachment to biomolecules," <i>Bioconjugate Chemistry</i> , 3:154-159, 1992.
<i>[Signature]</i>	C150	Maraganore <i>et al.</i> , "Structure of the hirugen and hirulog 1 complexes of $\alpha$ -thrombin," <i>J. Mol. Biol.</i> , 221:1379-1393, 1991.

25356403.1

EXAMINER: *[Signature]*DATE CONSIDERED: *5/31/05*

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No. UTSC:664USC1	Serial No. 10/672,763
List of Patents and Publications for Applicant's  INFORMATION DISCLOSURE STATEMENT  (Use several sheets if necessary)		Applicants David Yang <i>et al.</i>	
		Filing Date: September 26, 2003	Group: Unknown <i>148</i>
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 1</i>	Other Art <i>See Page 1</i>	

### Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
<i>W</i>	C151	Marti and Risau, "Systematic hypoxia changes the organ-specific distribution of vascular endothelial growth factor and its receptors," <i>Proc. Natl. Acad. Sci., USA</i> , 95:15809-15814, 1998.
	C152	Martin <i>et al.</i> , "Enhanced binding of the hypoxic cell marker [ <sup>3</sup> H]fluoromisonidazole in ischemic myocardium," <i>J Nucl Med</i> , 30:194-201, 1989.
	C153	Mason <i>et al.</i> , "99mTc-desferoxamine: production, stability and solute clearance measurements after aerosolization," <i>J. Nuclear Med.</i> , 31:908, Abstract No. 865, 1990.
	C154	Masui <i>et al.</i> , "Growth inhibition of human tumor cells in athymic mice by anti-epidermal growth factor receptor monoclonal antibodies," <i>Cancer Research</i> , 44:1002-1007, 1984.
	C155	Mather <i>et al.</i> , "Tumour cell uptake of technetium dithiocarbamate complexes," <i>J. Nuclear Med.</i> , 38:186P, Abstract No. 797, 1997.
	C156	Mathew <i>et al.</i> , "Synthesis and evaluation of some water-soluble prodrugs and derivatives of taxol with antitumor activity," <i>J. Med. Chem.</i> , 35:145-151, 1992.
	C157	Mathias <i>et al.</i> , "Tumor-selective radiopharmaceutical targeting via receptor-mediated endocytosis of Gallium-67-deferoxamine-folate," <i>J Nucl Med</i> , 37:1003-1008, 1996.
	C158	Mathias <i>et al.</i> , "Indium-111-DTPA-folate as a radiopharmaceutical for targeting tumor-associated folate binding protein," <i>J Nucl Med</i> , (Supplement) 38:133P, 1997.
	C159	Mathias <i>et al.</i> , "Synthesis of Tc-99m-DTPA-folate and preliminary evaluation as a folate-receptor-targeted radiopharmaceutical," <i>J Nucl Med</i> , (Supplement); 38:87P, 1997.
	C160	Meares <i>et al.</i> , "Macrocyclic chelates of radiometals for diagnosis and therapy," <i>British J. Cancer</i> , 62:21-26, 1990.
	C161	Mease <i>et al.</i> , "Comparison of renal agents for detecting unilateral acute ischemic/reperfusion renal injury in rats," <i>J. Nuclear Med.</i> , 36:231P, Abstract No. 1033, 1995.
	C162	Mendelsohn <i>et al.</i> , "Anti-epidermal growth factor receptor monoclonal antibodies may inhibit A431 tumor cell proliferation by blocking autocrine pathway," <i>Trans. Assoc. Am. Phys.</i> , 100:173-178, 1987.
	C163	Mendelsohn, "Epidermal growth factor receptor inhibition by a monoclonal antibody as anticancer therapy," <i>Clinical Cancer Research</i> , 3:2703-2707, 1997.

25356403.1




EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No. UTSC:664USC1	Serial No. 10/672,763
List of Patents and Publications for Applicant's  INFORMATION DISCLOSURE STATEMENT  (Use several sheets if necessary)		Applicants David Yang <i>et al.</i>	
		Filing Date: September 26, 2003	Group: Unknown 16/8
U.S. Patent Documents See Page 1	Foreign Patent Documents See Page 1	Other Art See Page 1	

### Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C164	Michiels <i>et al.</i> , "Simultaneous estimation of effective renal plasma flow and glomerular filtration rate using tc-99m-ec," <i>J. Nuclear Med.</i> , 37:91P, Abstract No. 355, 1996.
	C165	Miltross <i>et al.</i> , "Relationship of mitotic arrest and apoptosis to antitumor effect of paclitaxel," <i>J. National Cancer Institute</i> , 88(18):1308-1314, 1996.
	C166	Mitchell <i>et al.</i> , "Active-specific immunotherapy for melanoma," <i>J. Clin. Oncol.</i> , 8(5):856-869, 1990.
	C167	Mochizuki <i>et al.</i> , "Synthesis of poly-L-glutamates containing 5-substituted uracil moieties," <i>Nucleic Acids Symp. Ser.</i> , 16:121-124, 1985.
	C168	Modjahedi <i>et al.</i> , "The receptor for EGF and its ligands: expression, prognostic value and target for therapy in cancer (review)," <i>Int. J. Oncology</i> , 4(2):277-296, 1994.
	C169	Moller <i>et al.</i> , "Biologic activities of naturally occurring human insulin receptor mutations," <i>J. Biol. Chem.</i> , 266:10995-11001, 1991.
	C170	Moran, "Technetium- <sup>99m</sup> -EC and other potential new agents in renal nuclear medicine," <i>Seminars in Nucl. Med.</i> , 29: 91-101, 1999.
	C171	Morton <i>et al.</i> , "Comparison of 2-point postural drainage with diuresis renography in the assessment hydronephrosis," <i>J. Nuclear Med.</i> , 37:46P, Abstract No. 174, 1996.
	C172	Morton <i>et al.</i> , "Prolongation of survival in metastatic melanoma after active specific immunotherapy with a new polyvalent melanoma vaccine," <i>Ann. Surg.</i> , 216(4):463-482, 1992.
	C173	Mosmann, "Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assay," <i>J. Immunol. Methods</i> , 65:55-63, 1983.
	C174	Mrhac <i>et al.</i> , "Abnormal first-pass flow through the azygos vein from valsalva maneuver," <i>Clinical Nucl. Med.</i> , 21:331-332, 1996.
	C175	Nicolaou <i>et al.</i> , "Design, synthesis, and biological activity of protaxols," <i>Nature</i> , 364:464-466, 1993.
	C176	Nosco <i>et al.</i> , "Development of a kit formulation for <sup>99m</sup> Tc-mag3 of very high purity and very high stability," <i>J. Nuclear Med.</i> , 31:908, Abstract No. 863, 1990.
	C177	Offield <i>et al.</i> , "PDX-1 is required for pancreatic outgrowth and differentiation of the rostral duodenum," <i>Development</i> , 122:983-995, 1996.

25356403.1

EXAMINER:

DATE CONSIDERED: 5/31/05

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.



Form PTO-1449 (modified)		Atty. Docket No. UTSC:664USC1	Serial No. 10/672,763
List of Patents and Publications for Applicant's  INFORMATION DISCLOSURE STATEMENT  (Use several sheets if necessary)		Applicants David Yang <i>et al.</i>	
		Filing Date: September 26, 2003	Group: Unknown <i>1618</i>
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 1</i>	Other Art <i>See Page 1</i>	

### Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
<i>[Handwritten mark]</i>	C178	Oldham <i>et al.</i> , "Comparison of action of paclitaxel and poly (L-glutamic acid)-paclitaxel conjugate in human breast cancer cells," <i>Int. J. Oncol.</i> , 16(1):125-132, 2000.
<i>[Handwritten mark]</i>	C179	Olexa <i>et al.</i> , "Radiolabeling of fibrinogen using the lodogen technique," <i>Throm. Res. Gen. Dept. Biochem.</i> , pp 593-596, 1982.
	C180	Omelyanenko <i>et al.</i> , "HPMA copolymer-anticancer drug-OV-TL16 antibody conjugates: influence of synthesis on the binding affinity to OVCAR-3 ovarian carcinoma cells in vitro," <i>J. Drug Targeting</i> , 3:357-373, 1996.
	C181	Omelyanenko <i>et al.</i> , "HPMA copolymer-anticancer drug-OV-TL16 antibody conjugates II. Processing in epithelial ovarian carcinoma cells in vitro," <i>International Journal of Cancer</i> , 75(4):600-608, 1998.
	C182	Orr <i>et al.</i> , "Similarity of folate receptor expression in UMSCC 38 cells to squamous cell carcinoma differentiation markers," <i>J Natl Cancer Inst</i> , 87:299-303, 1995.
	C183	Ozanne <i>et al.</i> , "Over-expression of the EGF receptor is a hallmark of squamous cell carcinomas," <i>J. Pathol.</i> , 149:9-14, 1986.
	C184	Ozker <i>et al.</i> , "Technetium- <sup>99m</sup> -N,N-ethylenedicysteine-a comparative study of renal scintigraphy with technetium- <sup>99m</sup> -MAG3 and iodine-131-OIH in patients with obstructive renal disease," <i>J. Nucl. Med.</i> , 35:840-845, 1994.
	C185	Pedley <i>et al.</i> , "The potential for enhanced tumour localisation by poly(ethylene glycol) modification of anti-CEA antibody," <i>British J. Cancer</i> , 70:1126-1130, 1994.
	C186	Petrak <i>et al.</i> , "Transport of macromolecules across the capillary walls," <i>Adv. Drug Deliv. Review</i> , 3:191-214, 1989.
	C187	Phillips-Hughes <i>et al.</i> , "Restenosis: pathophysiology and preventive strategies," <i>JVIR</i> , 7:321-333, 1996.
<i>[Handwritten mark]</i>	C188	Pietersz <i>et al.</i> , "Specific in vitro anti-tumor activity of methotrexate-monoclonal antibody conjugates prepared using human serum albumin as an intermediary," <i>Immunol. Cell Biol.</i> , 66:43-49, 1988.
<i>[Handwritten mark]</i>	C189	Pimm <i>et al.</i> , "Differences in tumor and normal tissue concentrations of iodine and indium labeled monoclonal antibody II: biodistribution studies in mice with human tumor xenografts," <i>Dur. J. Nucl. Med.</i> , 11:300-304, 1985.

25356403.1

EXAMINER:

DATE CONSIDERED: *5/31/87*

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No. UTSC:664USC1	Serial No. 10/672,763
List of Patents and Publications for Applicant's  INFORMATION DISCLOSURE STATEMENT  (Use several sheets if necessary)		Applicants David Yang <i>et al.</i>	
		Filing Date: September 26, 2003	Group: Unknown <i>10/18</i>
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 1</i>	Other Art <i>See Page 1</i>	

### Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
<i>10/18</i>	C190	Pimm <i>et al.</i> , "Strategies for labelling branched polypeptides with a poly (L-Lysine) backbone with radioiodines 123I, 125I, 131I) and radiometals (111In, 51Cr) for biodistribution studies and radiopharmaceutical development," <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 36(2):157-172, 1995.
	C191	Piper <i>et al.</i> , "A synthetic approach to poly( $\gamma$ -glutamyl) conjugates of methotrexate," <i>J. Med. Chem.</i> , 26:291-294, 1983.
	C192	Pirmettis <i>et al.</i> , "Synthesis and characterization of the tcd(ec) complex, a renal imaging agent," <i>J. Nuclear Med.</i> , 35:263P, Abstract No. 1079, 1994.
	C193	Popovici <i>et al.</i> , "The influence of some antibiotics on hexokinase and pyruvate-kinase activity in the rat liver and kidney," <i>Arch. int. Pharmacodyn.</i> , 193:80-86, 1971.
	C194	Potamianos <i>et al.</i> , "Radioimmunoscinigraphy and radioimmunotherapy in cancer: principles and application," <i>Anticancer Research</i> , 20(2A):925-948, 2000.
	C195	Prvulovich <i>et al.</i> , "Clinical evaluation of technetium- <sup>99m</sup> -L,L-ethylenedicycysteine in patients with chronic renal failure," <i>J. Nucl. Med.</i> , 38:809-814, 1997.
	C196	Putnam <i>et al.</i> , "Polymer conjugates with anticancer activity," <i>Polymer Science</i> , 122:55-123, 1995.
	C197	Quadri <i>et al.</i> , "Effects of linker chemistry on the pharmacokinetics of radioimmunoconjugates," <i>Quart. J. Nucl. Med.</i> , 42:250-261, 1998.
	C198	Raffauf <i>et al.</i> , "Colchicine. Derivatives of trimethylcolchicinic acid," <i>J. Am Chem Soc.</i> , 75:5292-5294, 1953.
	C199	Rasey <i>et al.</i> , "Characterization of the binding of labeled fluoromisonidazole in cells in vitro," <i>Radiat Res</i> , 122:301-308, 1990.
	C200	Rasey <i>et al.</i> , "Radiolabeled fluoromisonidazole as an imaging agent for tumor hypoxia," <i>Int. J. Radiat Oncol. Biol Phys</i> , 17:985-991, 1989.
	C201	Ratner and Clarke, "The action of formaldehyde upon cysteine," <i>J. Am Chem. Soc.</i> , 59:200-206, 1937.
<i>10/18</i>	C202	Ravindranath <i>et al.</i> , "Quantitation of the density of cell surface carbohydrate antigens on cancer cells with a sensitive cell-suspension ELISA," <i>J. Immunol. Methods</i> , 16(197):51-67, 1996.

25356403.1

EXAMINER:

DATE CONSIDERED: *5/3/05*

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No. UTSC:664USC1	Serial No. 10/672,763
List of Patents and Publications for Applicant's  INFORMATION DISCLOSURE STATEMENT  (Use several sheets if necessary)		Applicants David Yang <i>et al.</i>	
		Filing Date: September 26, 2003	Group: Unknown <i>16/8</i>
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 1</i>	Other Art <i>See Page 1</i>	

### Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
<i>[Signature]</i>	C203	Reilly <i>et al.</i> , "A comparison of EGF and Mab 528 labeled within for imaging human breast cancer," <i>J. Nucl. Med.</i> , 41:903-911, 2000.
<i>[Signature]</i>	C204	Remington's Pharmaceutical Sciences, 19 <sup>th</sup> Ed., Mach Printing Company, 1990, Smith and Rutlage, 1975.
<i>[Signature]</i>	C205	Rihova <i>et al.</i> , "Antiproliferative effect of a lectin- and anti-thy-1.2 antibody-targeted HPMA copolymer-bound doxorubicin on primary and metastatic human colorectal carcinoma and on human colorectal carcinoma transfected with the mouse thy-1.2 gene," <i>Bioconjugate Chemistry</i> , 11(5):664-673, 2000.
<i>[Signature]</i>	C206	Rihova, "Receptor-mediated targeted drug or toxin delivery," <i>Adv. Drug Deliv. Rev.</i> , 29:273-289, 1998.
<i>[Signature]</i>	C207	Rogers <i>et al.</i> , "Neomycin effects on glucose transport by rat small intestine," <i>Digestion</i> , 1:159-164, 1968.
<i>[Signature]</i>	C208	Rosenberg <i>et al.</i> , "Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients," <i>Ann. Surg.</i> , 210(4):474-548, 1989.
<i>[Signature]</i>	C209	Ross <i>et al.</i> , "Differential regulation of folate receptor isoforms in normal and malignant tissue in vivo and in established cell lines," <i>Cancer</i> , 73:2432-2443, 1994.
<i>[Signature]</i>	C210	Roth <i>et al.</i> , "Gene therapy for cancer: what have the inventors done and where are the inventors going?" <i>J. Natl. Can. Inst.</i> , 89(1):21-39, 1997.
<i>[Signature]</i>	C211	Rowinsky <i>et al.</i> , "Paclitaxel (taxol)," <i>New England Journal of Medicine</i> , 332:1004-1014, 1995.
<i>[Signature]</i>	C212	Rowinsky <i>et al.</i> , "Phase I and pharmacologic study of paclitaxel and cisplatin with granulocyte colony-stimulating factor: neuromuscular toxicity is dose-limiting," <i>J. Clin. Oncol.</i> , 11(10):2010-2020, 1993.
<i>[Signature]</i>	C213	Rowland <i>et al.</i> , "Suppression of tumor growth in mice by drug-antibody conjugate using a novel approach to linkage," <i>Nature</i> , 255:487-488, 1975.
<i>[Signature]</i>	C214	Sabbantini <i>et al.</i> , "Early findings in a phase I study of PG-Paclitaxel (CT2103 in recurrent ovarian or primary peritoneal cancer," <i>Proc. AACR-NCI-EORTC Int. Conference on Molecule Targets and Cancer Therapeutics</i> , Abs, 470:96, 2001.

25356403.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609. DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)

Form PTO-1449 (modified)		Atty. Docket No. UTSC:664USC1	Serial No. 10/672,763
List of Patents and Publications for Applicant's  INFORMATION DISCLOSURE STATEMENT  (Use several sheets if necessary)		Applicants David Yang <i>et al.</i>	
		Filing Date: September 26, 2003	Group: Unknown <i>11618</i>
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 1</i>	Other Art <i>See Page 1</i>	

### Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
<i>2</i>	C215	Sasaki <i>et al.</i> , "Assessment of antioxidative ability in brain: imaging of glutathione localization with technetium-99m meso-hexamethyl propyleneamine," <i>J. Nuclear Med.</i> , 35:263P, Abstract No. 1083, 1994.
	C216	Sato <i>et al.</i> , "Simple estimation of fractional renal uptake of tc-99m mag3 using graphical analysis without syringe counting and renal depth correction," <i>J. Nuclear Med.</i> , 37:292P, Abstract No. 1303, 1996.
	C217	Seabold <i>et al.</i> , "Comparison of <sup>99m</sup> Tc-Methoxyisobutyl Isonitrile and <sup>201</sup> Tl Scintigraphy for Detection of Residual Thyroid Cancer After <sup>131</sup> I Ablative Therapy," <i>J. Nucl. Med.</i> , 40(9):1434-1440, 1999.
	C218	Semenza, "Regulation of mammalian O2 homeostasis by hypoxia-inducible factor 1," <i>Ann. Rev. Cell Dev. Biol.</i> , 15:551-578, 1999.
	C219	Serruys <i>et al.</i> , "A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease," <i>New England J. Medicine</i> , 331(8):489-495, 1994.
	C220	Seymour <i>et al.</i> , "Synthetic polymers conjugated to monoclonal antibodies: vehicles for tumor-targeted drug delivery," <i>Select. Cancer Therapeut.</i> , 7(2):59-73, 1991.
	C221	Shankar <i>et al.</i> , "Glucosamine infusion in rats mimics the beta-cell dysfunction of non-insulin-dependent diabetes mellitus," <i>Metabolism</i> , 47:573-577, 1998.
	C222	Shattuck <i>et al.</i> , "Validation of the two sample technique for measuring gfr in renal transplant patients," <i>J. Nuclear Med.</i> , 36:231P, Abstract No. 1036, 1995.
	C223	Shih <i>et al.</i> , "Anthracycline immunoconjugates prepared by a site-specific linkage via an amino-dextran intermediate carrier," <i>Cancer Res.</i> , 54:4192-4198, 1991.
	C224	Shimada <i>et al.</i> , "Biodistribution of liposomes containing synthetic galactose-terminated diacylglycerol-poly(ethylen glycol)s," <i>Biochimica et Biophysica Acta</i> , 1326:329-341, 1997.
	C225	Shuke <i>et al.</i> , "Modified renal counting method for estimation of tc-99m mag3 renal clearance," <i>J. Nuclear Med.</i> , 37:291P, Abstract No. 1301, 1996.
	C226	Sobel <i>et al.</i> , "Noninvasive estimation of regional myocardial oxygen consumption by positron emission tomography with carbon-11 acetate in patients with myocardial infaction," <i>J. Nucl. Med.</i> , 30:1798-1808, 1989.

25356403.

EXAMINER:

DATE CONSIDERED: *5/3/05*

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No. UTSC:664USC1	Serial No. 10/672,763
List of Patents and Publications for Applicant's  INFORMATION DISCLOSURE STATEMENT  (Use several sheets if necessary)		Applicants David Yang <i>et al.</i>	
		Filing Date: September 26, 2003	Group: Unknown <i>11618</i>
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 1</i>	Other Art <i>See Page 1</i>	

### Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
<i>20</i>	C227	Stoffel <i>et al.</i> , "Evaluation of technetium-99m-L,1-ec in renal transplant recipients: a comparative study with technetium- <sup>99m</sup> -MAG3 and iodine-125-OIH, <i>J. Nucl. Med.</i> , 35:1951-1958, 1994.
	C228	Stuttle <i>et al.</i> , "Imaging of bone infection with labelled white blood cells: role of contemporaneous bone marrow imaging," <i>Dept. Dia. Rad.</i> , pp 148-151, 1990.
	C229	Subramanian <i>et al.</i> , "Transchelation reactions in labeling ecd with tc-99m," <i>J. Nuclear Med.</i> , 31:908, Abstract No. 867, 1990.
	C230	Sudimack <i>et al.</i> , "Targeted delivery via folate receptor," <i>Adv. Drug Deliv. Rev.</i> , 41:147-162, 2000.
	C231	Sun <i>et al.</i> , "Idium(III) and Gallium(III) Complexes of Bis(aminoethanethiol) Ligands with Different Denticities: Stabilities, Molecular Modeling, and in Vivo Behavior," <i>Journal of Medicinal Chemistry</i> , 39(2):458(1996).
	C232	Surma <i>et al.</i> , "Usefulness of Tc-99m-N,N'-ethylene-1-dicysteine complex for dynamic kidney investigations," <i>Nucl Med Comm</i> , 15:628- 635, 1994.
	C233	Surwit <i>et al.</i> , "Clinical assessment to f In-CYT-103 immunoscintigraphy in ovarian cancer," <i>Gynecol. Oncol.</i> , 48:285-292, 1993.
	C234	Suzuki <i>et al.</i> , "A modified graphic method for estimation of glomerular filtration index using dynamic renal images with tc-99m dtpa," <i>J. Nuclear Med.</i> , 36:231P, Abstract No. 1035, 1995.
	C235	Tait and Smith, "Site-specific mutagenesis of annexin V: role of residues from Arg-200 to Lys-207 in phospholipid binding," <i>Arch Biochem Biophys</i> , 288:141-144, 1991.
	C236	Takamizawa <i>et al.</i> , "Differential apoptosis gene expression in pediatric tumors of the kidney," <i>J. Ped. Surg.</i> , 35(2):390-395, 2000.
	C237	Takashina <i>et al.</i> , "Comparative pharmacokinetic properties of murine monoclonal antibody A7 modified with neocarzinostatin, dextran and polyethylene glycol," <i>Jpn. J. Cancer Res.</i> , 82:1145-1150, 1991.
	C238	Tam, "Synthetic peptide vaccine design: synthesis and properties of a high-density multiple antigenic peptide system," <i>Proc. Natl. Acad. Sci., USA</i> , 85:5409-5413, 1988.
	C239	Taylor <i>et al.</i> , "Comparison of tc-99m0(n,n1-ethylenedicysteine isomers in rats and in normal volunteers," <i>J. Nuclear Med.</i> , 37:46P-47P, Abstract No. 177, 1996.

25356403.1

EXAMINER:

DATE CONSIDERED: *5/3/05*

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No. UTSC:664USC1	Serial No. 10/672,763
List of Patents and Publications for Applicant's  INFORMATION DISCLOSURE STATEMENT  (Use several sheets if necessary)		Applicants David Yang <i>et al.</i>	
		Filing Date: September 26, 2003	Group: Unknown <i>11/5</i>
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 1</i>	Other Art <i>See Page 1</i>	

### Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
<i>[Handwritten mark]</i>	C240	Taylor <i>et al.</i> , "Comparison of technetium- <sup>99m</sup> -LL-EC isomers in rats and humans," <i>J. Nucl. Med.</i> , 38:821-826, 1997.
<i>[Handwritten mark]</i>	C241	Tomalia <i>et al.</i> , "Starburst dendrimers: molecular-level control of size, shape, surface chemistry, topology and flexibility from atoms to macroscopic matter," <i>Angew. Chem. Int. Ed. Engl.</i> , 29:138-175, 1990.
	C242	Torchilin <i>et al.</i> , "Chelating polymer modified monoclonal antibodies for radioimmunodiagnostics and radioimmunotherapy," <i>J. Controlled Release</i> , 24:111-118, 1993.
	C243	Tsukamoto <i>et al.</i> , "The quantitation of absolute tc-99m-dmsa renal uptake in children from planar posterior-view method," <i>J. Nuclear Med.</i> , 37:291P, Abstract No. 1299, 1996.
	C244	Tubis <i>et al.</i> , "The preparation of <sup>99m</sup> technetium-labelled cystine, methionine and synthetic polypeptide and their distribution in mice," <i>Int. Journ. Appl. Rad. Isotop.</i> , 19:835-840, 1968.
	C245	Tuli <i>et al.</i> , "Comparison of a simplified quantitation of tc-99m mag-3 renogram to core needle biopsy in the diagnosis of renal transplant rejection," <i>J. Nuclear Med.</i> , 37:289P, Abstract No. 1290, 1996.
	C246	Ugar <i>et al.</i> , "The diagnosis of renovascular hypertension with technetium-99m-ethylenedicycysteine captopril scintigraphy," <i>Investigative Radiology</i> , 31:497-501, 1996.
	C247	Ugur <i>et al.</i> , "Renovascular hypertension due to takayasu's arteritis demonstrated by Tc- <sup>99m</sup> ethylenedicycysteine captopril scintigraphy," <i>Clinical Nuclear Medicine</i> , 21:714-716, 1996.
	C248	Ugur <i>et al.</i> , "Technetium- <sup>99m</sup> -ethylenedicycysteine in the diagnosis and follow-up of renovascular hypertension," <i>Investigative Radiology</i> , 31:378-381, 1996.
	C249	Ugur <i>et al.</i> , "Technetium- <sup>99m</sup> -ethylenedicycysteine: an alternative agent to detect renovascular hypertension," <i>J. of Nuclear Med.</i> , 38:1662-1664, 1997.
<i>[Handwritten mark]</i>	C250	Ugur <i>et al.</i> , "The diagnosis of renovascular hypertension with tc-99m ethylenedicycysteine captopril scintigraphy," <i>J. Nuclear Med.</i> , 37:291P, Abstract No. 1302, 1996.
<i>[Handwritten mark]</i>	C251	Valk <i>et al.</i> , "Hypoxia in human gliomas: Demonstration by PET with [ <sup>18</sup> F]fluoromisonidazole," <i>J Nucl Med</i> , 33:2133-2137, 1992.
<i>[Handwritten mark]</i>	C252	Van Heeswijk <i>et al.</i> , "The synthesis and characterization of polypeptide-adriamycin conjugates and its complexes with adriamycin Part 1," <i>J. Controlled Release</i> , 1:301-315, 1985.

25356403.1

EXAMINER:

DATE CONSIDERED: *5/30/05*

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No. UTSC:664USC1	Serial No. 10/672,763
List of Patents and Publications for Applicant's  INFORMATION DISCLOSURE STATEMENT  (Use several sheets if necessary)		Applicants David Yang <i>et al.</i>	
		Filing Date: September 26, 2003	Group: Unknown <i>11/18</i>
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 1</i>	Other Art <i>See Page 1</i>	

### Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
<i>[initials]</i>	C253	Van Nerom <i>et al.</i> , "Comparative evaluation of Tc-99m L,L-ethylenedicycysteine and Tc-99m MAG3 in volunteers," <i>Eur J Nucl Med</i> , 16:417, 1990.
<i>[initials]</i>	C254	Van Nerom <i>et al.</i> , "Comparison of renal excretion ocharacteristics of isomers l,l and d,d of tc-99m ethylenedicycysteine," <i>J. Nuclear Med.</i> , 31:806, Abstract No. 412, 1990.
	C255	Van Nerom <i>et al.</i> , "Optimalization of the labelling of ethylenedicycysteine (ec) with technetium-99m," <i>J. Labelled Compounds and Radiopharmaceuticals</i> , XXX:37-39, 1991.
	C256	Van Nerom <i>et al.</i> , "First experience in healthy volunteers with Tc-99m-L,L-ethylenedicycysteine, a new renal imaging agent," <i>Eur J Nucl Med</i> , 20:738-746, 1993.
	C257	Van Schepdael <i>et al.</i> , "Capillary electrophoretic analysis of ethylene dicysteine, a precursor of the radiopharmaceutical <sup>99m</sup> Tc ethylene dicysteine," <i>J. Chromatography B</i> , 697:251-254, 1997.
	C258	Vega <i>et al.</i> , "Targeting adriamycin to EGF receptors by site-specific conjugation of monoclonal antibody to poly(L-glutamic acid)," Division of Deagnostic Imaging and Departmetn of Experimental Therapeutics, U.T. M.D. Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX, USA.
	C259	Verbruggen <i>et al.</i> , "Evaluation of Tc-99m-L,L-ethylenedicycysteine as a potential alternative to Tc-99m MAG3," <i>Eur J Nucl Med</i> , 16:429, 1990.
	C260	Verbruggen <i>et al.</i> , "Is syn or anti orientation of the oxotechnetium and carboxyl group in tc-99m renal function agents affecting the renal excretion rate?" <i>J. Labelled Compounds and Radiopharmaceuticals</i> , XXX:86-88, 1991.
	C261	Verbruggen <i>et al.</i> , "Tc-99m l,l-ethylenedicycysteine, a potential alternative to tc-99m mag3," <i>J. Nuclear Med.</i> , 31:908, Abstract No. 864, 1990.
	C262	Verbruggen <i>et al.</i> , "Tc-99m-L,L-ethylenedicycysteine: A renal imaging agent. I. Labelling and evaluation in animals," <i>J Nucl Med</i> , 33:551-557, 1992.
<i>[initials]</i>	C263	Villevalois-Cam <i>et al.</i> , "Insulin-induced redistribution of the insulin-like growth factor II/mannose 6-phosphate receptor in intact rat liver," <i>J. Cell. Biochem.</i> , 77:310-322, 2000.
<i>[initials]</i>	C264	Vyas <i>et al.</i> , "Phosphatase-activated prodrugs of paclitaxel," Taxane Anticancer Agents: Basic Science and Current Status, <i>American Chemical Society</i> , Washington, DC, 124-137, 1995.
<i>[initials]</i>	C265	Wahl <i>et al.</i> , "Loss of normal p53 function conferees sensation to taxol by increasing g2/m arrest and apoptosis," <i>Nat. Med.</i> , 2(1):72-79, 1996.

253564031

EXAMINER:

DATE CONSIDERED: *8/31/05*

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No. UTSC:664USC1	Serial No. 10/672,763
List of Patents and Publications for Applicant's  INFORMATION DISCLOSURE STATEMENT  (Use several sheets if necessary)		Applicants David Yang <i>et al.</i>	
		Filing Date: September 26, 2003	Group: Unknown <i>W/S</i>
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 1</i>	Other Art <i>See Page 1</i>	

### Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
<i>W</i>	C266	Wahl, "Monoclonal antibodies in nuclear medicine," <i>Nuclear Medicine Annual</i> 1992, New York, Raven Press Ltd., 91-103, 1992.
	C267	Wang <i>et al.</i> , "Design and synthesis of [ <sup>111</sup> In]DTPA-folate for use as a tumor-targeted radiopharmaceutical," <i>Bioconjugate Chem.</i> , 8:673-679, 1997.
	C268	Wang <i>et al.</i> , "Synthesis, purification, and tumor cell uptake of Ga-67 deferoxamine-folate, a potential radiopharmaceutical for tumor imaging," <i>Bioconjugate Chem.</i> , 7:56-62, 1996.
	C269	Washburn <i>et al.</i> , "Reliable kit preparation of tc99m pentavalent dimercaptosuccinic acid [tc-99m (v) dmsa]," <i>J. Nuclear Med.</i> , 35:263P, Abstract No. 1080, 1994.
	C270	Weiss <i>et al.</i> , "Hypersensitivity reaction from taxol," <i>J. Clin. Oncol.</i> , 8(7):1263-1268, 1990.
	C271	Weitman <i>et al.</i> , "Cellular localization of the folate receptor: potential role in drug toxicity and folate homeostasis," <i>Cancer Res.</i> , 52:6708-6711, 1992b.
	C272	Weitman <i>et al.</i> , "The folate receptor in central nervous system malignancies of childhood," <i>J. Neuro-Oncology</i> , 21:107-112, 1994.
	C273	Weitman <i>et al.</i> , "Distribution of the folate receptor GP38 in normal and malignant cell lines and tissues," <i>Cancer Research</i> , 52:3396-3401, 1992.
	C274	Wells <i>et al.</i> , "Glycosylation of nucleocytoplasmic proteins: signal transduction and )-glcNAc," <i>Science</i> , 291:2376-2378, 2001.
	C275	Wen <i>et al.</i> , "Conjugation with 111In-DTPA-poly(ethylene glycol) improves imaging of anti-EGF receptor antibody C225," <i>J. Nuclear Medicine</i> , 42(10):1530-1537, 2001.
	C276	Wen <i>et al.</i> , "Improved radiolabeling of PEFylated protein: PEGylated annexin V for noninvasive imaging of tumor apoptosis," <i>Bioconjugate Chemistry</i> , 2002.
	C277	Wen <i>et al.</i> , "Poly(ethylene glucol) conjugated anti-EGF receptor antibody C225 with radiometal chelator attached to the termini of polymer chains," <i>Bioconjugate Chem.</i> , 12:545-553, 2001.
<i>W</i>	C278	Westerhof <i>et al.</i> , "Membrane transport of natural folates and antifolate compounds in murine L1210 leukemia cells: Role of carrier- and receptor- mediated transport systems," <i>Cancer Res.</i> , 51:5507-5513, 1991.

25356403.1

EXAMINER:


DATE CONSIDERED: *5/31/05*

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.



Form PTO-1449 (modified)		Atty. Docket No. UTSC:664USC1	Serial No. 10/672,763
List of Patents and Publications for Applicant's  INFORMATION DISCLOSURE STATEMENT  (Use several sheets if necessary)		Applicants David Yang <i>et al.</i>	
		Filing Date: September 26, 2003	Group: Unknown <i>11/28</i>
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 1</i>	Other Art <i>See Page 1</i>	

### Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C279	Wu <i>et al.</i> , "Apoptosis induced by and anti-epidermal growth factor receptor monoclonal antibody in a human colorectal carcinoma cell line and its delay by insulin," <i>J. Clin. Invest.</i> , 95:1897-1905, 1995.
	C280	Yamori <i>et al.</i> , "Potent antitumor activity of MS-247, a novel DNA minor groove binder, evaluated by an in vitro and in vivo human cancer cell line panel," <i>Cancer Res.</i> , 59:4042-4049, 1999.
	C281	Yang <i>et al.</i> , "Development of F-18-labeled fluoroerythronitroimidazole as a PET agent for imaging tumor hypoxia," <i>Radiology</i> , 194:795-800, 1995.
	C282	Yang <i>et al.</i> , "99mtc-ec-deoxyglucose: synthesis, cellular uptake, biodistribution and scintigraphic imaging," <i>J. Labelled Cpd. Radiopharm.</i> , 44:S513-S514, Abstract, 2001.
	C283	Yang <i>et al.</i> , "Imaging tumor folate receptors using 99mtc-ethylenedicysteine-folate," <i>Proceedings of the American Association for Cancer Research</i> , 40:259, Abstract #1720, 1999.
	C284	Yang <i>et al.</i> , "Molecular imaging using 99m-tc-ec-nitroimidazole, and 99mtc-ec-annexin v in tumor-bearing rodents," <i>Proceedings of the American Association for Cancer Research Annual Meeting</i> , 41:766, Abstract, 2000.
	C285	Yang <i>et al.</i> , "Noninvasive assesment of tumor hypoxia with 99mTc labeled metronidazole," <i>Pharm. Research</i> , 16:743-750, 1999.
	C286	Yasui <i>et al.</i> , "Expression of epidermal growth factor receptor in human gastric and colonic carcinomas," <i>Cancer Res.</i> , 48:137-141, 1995.
	C287	Yokoyama <i>et al.</i> , "Polymer micelles as novel drug carrier: adriamycin-conjugated poly(ethylen glycol)-poly(aspartic acid) block copolymer," <i>J. Controlled Release</i> , 11:269-278, 1990.
	C288	Yokoyama <i>et al.</i> , "Preparation of micelle-formin polymer-drug conjugates," <i>Bioconjugate Chem.</i> , 3:295-301, 1992.
	C289	Yoshino <i>et al.</i> , "Differential effects of troglitazone and D-chiroinositol on glucosamine-induced insulin resistance in vivo in rats," <i>Metabolism</i> . 48:1418-23, 1999.
	C290	Young <i>et al.</i> , "Influence of immunoglobulin heavy and light-chain expression on B-cell differentiation," <i>Genes Develop.</i> , 8:1043-1057, 1994.
	C291	Zakko <i>et al.</i> , "Biliary excretion of Tc- <sup>99m</sup> ec in renal studies," <i>Clinical Nuclear Medicine</i> , 23:417-419, 1998.

25356403.

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No. UTSC:664USC1	Serial No. 10/672,763
List of Patents and Publications for Applicant's  INFORMATION DISCLOSURE STATEMENT  (Use several sheets if necessary)		Applicants David Yang <i>et al.</i>	
		Filing Date: September 26, 2003	Group: Unknown <i>11/28</i>
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 1</i>	Other Art <i>See Page 1</i>	

### Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
<i>[Signature]</i>	C292	Zareneyrizi <i>et al.</i> , "Synthesis of [ <sup>99m</sup> Tc] ethylenedicysteine-colchicine for evaluation of antiangiogenic effect," <i>Anti-Cancer Drugs</i> , 10:685-692, 1999.

25356403.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)

Form PTO-1449 (modified)

Atty. Docket No.

Serial No.

UTSC:664USC1

10/672,763

List of Patents and Publications for Applicant's

Applicant

David Yang *et al.*

## INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Filing Date:

September 26, 2003

Group:

1616

U.S. Patent Documents

See Page 1

Foreign Patent Documents

See Page 1

Other Art

See Page 1

## U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.
	A44	4,279,992	7/21/81	Boguslaski <i>et al.</i>	435	7	10/23/79
	A45	4,789,542	12/06/88	Goodman and Knapp, Jr.	424	1.1	4/29/86
	A46	4,824,659	4/25/89	Hawthorne	424	1.1	6/07/85
	A47	5,013,556	5/07/91	Woodle <i>et al.</i>	424	450	10/20/89
	A48	5,356,793	10/18/94	Koezuka <i>et al.</i>	435	32	2/01/91
	A49	5,643,883	6/01/97	Marchase and Darbha	514	23	1/19/95
	A50	5,688,487	11/18/97	Linder <i>et al.</i>	424	1.65	6/06/95
	A51	5,834,266	11/10/98	Crabtree <i>et al.</i>	435	172.3	8/18/94
	A52	5,877,289	3/02/99	Thorpe and Edgington	530	387.1	6/07/95
	A53	5,891,468	4/06/99	Martin and Zalipsky	424	450	10/10/97
	A54	6,033,884	3/07/00	Woo <i>et al.</i>	435	172.3	12/14/93
	A55	6,054,436	4/25/00	Crabtree <i>et al.</i>	514	31	5/29/98

## Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No
	B11	WO 98/08859	3/05/98	WIPO			English

## Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C340	Boersma <i>et al.</i> , "Quantification of apoptotic cells with fluorescein isothiocyanate-labeled annexin V in Chinese hamster ovary cell cultures treated with cisplatin," <i>Cytometry</i> , 24:123-130, 1996.
	C341	Cafaggi <i>et al.</i> , "Synthesis and antitumor activity of a new cis-diammineplatinum (III) complex containing procaine hydrochloride," <i>Anticancer Research</i> , 12:2285-2292, 1992.

25497736.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No. UTSC:664USC1	Serial No. 10/672,763
List of Patents and Publications for Applicant's  INFORMATION DISCLOSURE STATEMENT  (Use several sheets if necessary)		Applicant David Yang <i>et al.</i>	
		Filing Date: September 26, 2003	Group: 1616 1618
U.S. Patent Documents See Page 1	Foreign Patent Documents See Page 1	Other Art See Page 1	

### Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C342	Cammisuli <i>et al.</i> , "SDZ 281-977: a modified partial structure of lavendustin A that exerts potent and selective antiproliferative activities in vitro and in vivo," <i>Int J Cancer</i> , 65:351-359, 1996.
	C343	Chakrabarti <i>et al.</i> , "Interaction of the antitumor antibiotic chromomycin A3 with glutathione, a sulfhydryl agent, and the effect upon its DNA binding properties," <i>Biochemical Pharmacology</i> , 56:1471-1479, 1998.
	C344	Connors, "Anticancer drug development: the way forward," <i>The Oncologist</i> , 1:180-181, 1996.
	C345	Guo and Gallo, "Selective protection of 2', 2'-difluorodeoxycytidine (Gemcitabine)," <i>J Org Chem</i> , 64:8319-8322, 1999.
	C346	Hirsch <i>et al.</i> , "PK11195, a ligand of the mitochondrial benzodiazepine receptor, facilitates the induction of apoptosis and reverses Bcl-2-mediated cytoprotection," <i>Experimental Cell Research</i> , 241:426-434, 1998.
	C347	Hjarnaa <i>et al.</i> , "CHS 828, a novel pyridyl cyanoguanidine with potent antitumor activity in vitro and in vivo," <i>Cancer Res.</i> , 59:5751-5757, 1999.
	C348	Inoue <i>et al.</i> , "Evaluation of In-111 DTPA-paclitaxel scintigraphy to predict response on murine tumors to paclitaxel," <i>Annals of Nuclear Medicine</i> , 13(3):169-174, 1999.
	C349	Jiang <i>et al.</i> , "Antitumor activity of didemnin B in the human tumor stem cell assay," <i>Cancer Chemother Pharmacol</i> , 11:1-4, 1983.
	C350	Jiang <i>et al.</i> , "3-(Iodoacetamido)-benzoylurea: a novel cancericidal tubulin ligand that inhibits microtubule polymerization, phosphorylates bcl-2, and induces apoptosis in tumor cells," <i>Cancer Res.</i> , 58:5389-5395, 1998.
	C351	LeClerc and Cedergren, "Modeling RNA-ligand interactions: the rev-binding element RNA-aminoglycoside complex," <i>J Med Chem</i> , 41:175-182, 1998.
	C352	Lundberg <i>et al.</i> , "Conjugation of an anti-B-cell lymphoma monoclonal antibody, LL2, to long-circulating drug-carrier lipid emulsions," <i>J Pharm Pharmacol</i> , 51:1099-1105, 1999.
	C353	McGahon <i>et al.</i> , "Chemotherapeutic drug-induced apoptosis in human leukaemic cells is independent of the Fas (APO-1/CD95) receptor/ligand system," <i>British Journal of Haematology</i> , 101:539-547, 1998.
	C354	Meyer <i>et al.</i> , "Tryptophan hydrolase antibodies used in the diagnosis of carcinoid," <i>Hepato-Gastroenterology</i> , 45:1522-1526, 1998.

25497736.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No. UTSC:664USC1	Serial No. 10/672,763
List of Patents and Publications for Applicant's  INFORMATION DISCLOSURE STATEMENT  (Use several sheets if necessary)		Applicant David Yang <i>et al.</i>	
		Filing Date: September 26, 2003	Group: 1616 1618
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 1</i>	Other Art <i>See Page 1</i>	

### Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C355	Murray <i>et al.</i> , "Matrix metalloproteinase-1 is associated with poor prognosis in oesophageal cancer," <i>Journal of Pathology</i> , 185:256-261, 1998.
	C356	Palyi <i>et al.</i> , "Effects of methylacetylenic putrescine, and ornithine decarboxylase inhibitor and potential novel anticancer agent, on human and mouse cancer cell lines," <i>Anti-Cancer Drugs</i> , 10:103-111, 1999.
	C357	Pavicevic <i>et al.</i> , "Serum tumor marker CYFRA 21-1 in the diagnostics of NSCLC lung cancer," <i>Coll Antropol</i> , 22(2):629-635, 1998.
	C358	Pavlik <i>et al.</i> , "Properties of anticancer agents relevant to in vitro determinations of human tumor cell sensitivity," <i>Cancer Chemother Pharmacol</i> , 11:8-15, 1983.
	C359	Rasey <i>et al.</i> , "Radiolabeled fluoromisonidazole as an imaging agent for tumor hypoxia," <i>Int J Radiation Oncology Biol Phys</i> , 17:985-991, 1989.
	C360	Rasey <i>et al.</i> , "Characteristics of the binding of labeled fluoromisonidazole in cells in vitro," <i>Radiation Research</i> , 122:301-308, 1990.
	C361	Reutelingsperger and van Heerde, "Annexin V, the regulator of phosphatidylserine-catalyzed inflammation and coagulation during apoptosis," <i>Cell Mol Life Sci</i> , 53:527-532, 1997.
	C362	Thompson, "Apoptosis in the pathogenesis and treatment of disease," <i>Science</i> , 267:1456-1462, 1995.
	C363	Tolomeo <i>et al.</i> , "The CD95/CD95 ligand system is not the major effector in anticancer drug-mediated apoptosis," <i>Cell Death and Differentiation</i> , 5:735-742, 1998.
	C364	Van den Eijnde <i>et al.</i> , "In situ detection of apoptosis during embryogenesis with annexin V: from whole mount to ultrastructure," <i>Cytometry</i> , 29:313-320, 1997.
	C365	Wright <i>et al.</i> , "Aminoglycoside antibiotics: structures, functions, and resistance," In: <i>Resolving the Antibiotic Paradox</i> , Rosen and Mobashery eds, Kluwer Academic/Plenum Pub NY, 1998.
	C366	Yoshinari <i>et al.</i> , "Mode of action of a new indolocarbazole anticancer agent, J-107088, targeting topoisomerase I," <i>Cancer Res.</i> , 59:4271-4275, 1999.

25497736.1

EXAMINER: 

DATE CONSIDERED: 5/31/08

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)

Atty. Docket No.

UTSC:664USC1

Serial No.

10/672,763

List of Patents and Publications for Applicant's

Applicants

David Yang *et al.*

## INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Filing Date:

September 26, 2003

Group:

Unknown 1618

U.S. Patent Documents

See Page 1

Foreign Patent Documents

See Page 1

Other Art

See Page 1

## U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.
<i>AD</i>	A43	5,268,163	12/07/93	Verbruggen	424	1.1	4/10/91

## Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No
<i>AD</i>	B8	WO 01/80906	11/01/01	PCT	—	—	English
<i>AD</i>	B9	WO 01/91807	12/06/01	PCT	—	—	English
<i>AD</i>	B10	WO 91/16076	10/31/91	PCT	—	—	English

## Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
<i>AD</i>	C293	Alauddin and Conti, "Synthesis and preliminary evaluation of 9-(4-{[18F]-Fluoro-3-Hydroxymethylbutyl}guanine ([18F]FHBG): a new potential imaging agent for viral infection and gene therapy," <i>Nucl. Med. Biol.</i> , 25:175-180, 1998.
<i>AD</i>	C294	Alauddin <i>et al.</i> , "9-[(3-18F)-fluoro-1-hydroxy-2-propoxy)methyl]guanine ([18F]-FHPG): a potential imaging agent of viral infection and gene therapy using PET," <i>Nucl. Med. Biol.</i> , 23:787-792, 1996.
<i>AD</i>	C295	Alauddin <i>et al.</i> , "Evaluation of 9-[(3-18F)-fluoro-1-hydroxy-2-propoxy)methyl]guanine ([18F]-FHPG) in vitro and in vivo as probe for PET imaging of gene incorporation and expression in tumors," <i>Nucl. Med. Biol.</i> , 26:371-376, 1999.
<i>AD</i>	C296	Alauddin <i>et al.</i> , "Receptor mediated uptake of a radiolabeled contrast agent sensitive to $\beta$ -galactosidase activity," <i>Nucl. Med. Biol.</i> , 30:261-265, 2002.
<i>AD</i>	C297	Appelbaum <i>et al.</i> , "The use of radiolabeled anti-CD33 antibody to augment marrow irradiation prior to marrow transplantation for acute myelogenous leukemia," <i>Transplantation</i> , 54(5):829-833, 1992.
<i>AD</i>	C298	Bertolini <i>et al.</i> , "Angiogenic growth factors and endostatin in non-Hodgkin's lymphoma," <i>Br. J. Haematol.</i> , 106:5045, 1999.

25416404.1

EXAMINER: *AD*

DATE CONSIDERED: 5/31/05

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No. UTSC:664USC1	Serial No. 10/672,763
List of Patents and Publications for Applicant's  INFORMATION DISCLOSURE STATEMENT  (Use several sheets if necessary)		Applicants David Yang <i>et al.</i>	
		Filing Date: September 26, 2003	Group: Unknown 1618
U.S. Patent Documents See Page 1	Foreign Patent Documents See Page 1	Other Art See Page 1	

### Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C299	Blakenberg <i>et al.</i> , "In vivo detection and imaging of phosphatidylserine expression during programmed cell death," <i>Proc. Natl. Acad. Sci., USA</i> , 95:6349-6354, 1998.
	C300	Bormans <i>et al.</i> , "Synthesis and biological characteristics of the four stereoisomers of 99mTc-N, N'-bis-(mercaptoacetyl)2,3-diaminopropanoate," <i>Int. J. Rad. Appl. Instrum. B.</i> , 17(5):499-506, 1990.
	C301	Burian <i>et al.</i> , <i>Acta Otolaryngol.</i> , 119:289-292, 1999.
	C302	Cao, "Therapeutic potentials of angiostatin in the treatment of cancer," <i>Haematologica</i> , 84:643-650, 1999.
	C303	Deveraux and Reed, "IAP family proteins-suppressors of apoptosis," <i>Genes and Development</i> , 13:239-252, 1999.
	C304	Frisch and Screaton, "Anoikis mechanisms," <i>Curr. Opin. Cell Biol.</i> , 13:555-562, 2001.
	C305	Gambhir <i>et al.</i> , "A mutant herpes simplex virus type 1 thymidine kinase reporter gene shows improved sensitivity for imaging reporter gene expression with positron emission tomography," <i>Proc. Natl. Acad. Sci., USA</i> , 97(6):2785-2790, 2000.
	C306	Gambhir <i>et al.</i> , "Imaging adenoviral-directed reporter gene expression in living animals with positron emission tomography," <i>Proc. Natl. Acad. Sci., USA</i> , 96:2333-2338, 1999.
	C307	Gambhir <i>et al.</i> , "Imaging of adenoviral-directed herpes simplex virus type 1 thymidine kinase reporter gene expression in mice with radiolabeled ganciclovir," <i>J. Nucl. Med.</i> , 39:2003-2011, 1998.
	C308	Green and Evan, "A matter of life and death," <i>Cancer Cell</i> , 1:19-30, 2002.
	C309	Inoue <i>et al.</i> , "The prognostic value of angiogenesis factor expression for predicting recurrence and metastasis of bladder cancer after neoadjuvant chemotherapy and radical cystectomy," <i>Clin. Cancer Res.</i> , 6:4866-4873, 2000.
	C310	Ionov <i>et al.</i> , "Mutational inactivation of the proapoptotic gene BAX confers selective advantage during tumor clonal evolution," <i>Proc. Natl. Acad. Sci., USA</i> , 97(20):10872-10877, 2000.
	C311	Iyer <i>et al.</i> , "8-[18F]Fluoropenciclovir: an improved reporter probe for imaging HSV1-tk reporter gene expression in vivo using PET," <i>J. Nucl. Med.</i> , 42(1):96-105, 2001.

25416404.1

EXAMINER: 


DATE CONSIDERED: 5/31/05

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)

Form PTO-1449 (modified)		Atty. Docket No. UTSC:664USC1	Serial No. 10/672,763
List of Patents and Publications for Applicant's  INFORMATION DISCLOSURE STATEMENT  (Use several sheets if necessary)		Applicants David Yang <i>et al.</i>	
		Filing Date: September 26, 2003	Group: Unknown 1618
U.S. Patent Documents See Page 1	Foreign Patent Documents See Page 1	Other Art See Page 1	

### Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C312	Kao <i>et al.</i> , "Relationship of alveolar permeability and lung inflammation in patients with active diffuse infiltrative lung disease detected by 99Tcm-DTPA radioaerosol inhalation lung scintigraphy and quantitative 67Ga lung scans," <i>Nucl. Med. Commun.</i> , 15(10):850-854, 1994.
	C313	Kao <i>et al.</i> , "Role of radioisotope penile plethysmigraphy in the evaluation of penile hemodynamic of impotent patients," <i>J. Nuclear Med.</i> , 37:292P, Abstract No. 1304, 1996.
	C314	Kao <i>et al.</i> , "Tc-99m MIBI uptake in breast carcinoma and axillary lymph node metastases," <i>Clin. Nuc. Med.</i> , 19(10):898-900, 1994.
	C315	Lin <i>et al.</i> , "The role of Tc-99m MDP and Ga-67 imaging in the clinical evaluation of malignant fibrous histiocytoma," <i>Clin. Nucl. Med.</i> , 19(11):996-1000, 1994.
	C316	Liu <i>et al.</i> , "Apoptotic signals delivered through the T-cell receptor of a T-cell hybrid require the immediate-early gene <i>nur77</i> ," <i>Nature</i> , 367(6460):281-284, 1994. <del>1994.</del>
	C317	Liu <i>et al.</i> , "Detection of anaerobic odontogenic infections by fluorine-18 fluoromisonidazole," <i>Eur. J. Nucl. Med.</i> , 23(10):1384-1387, 1996.
	C318	Macapinlac <i>et al.</i> , "Callium-67-citrate imaging in nuclear oncology," <i>Nucl. Med. Biol.</i> , 21(5):731-738, 1994.
	C319	Makin and Hickman, "Apoptosis and cancer chemotherapy," <i>Cell Tissue Res.</i> , 301:143-152, 2000.
	C320	Martin <i>et al.</i> , "Noninvasive detection of hypoxic myocardium using fluorine-18 fluoromisonidazole and positron emission tomography," <i>J. Nucl. Med.</i> , 33(12):2202-2208, 1992.
	C321	Meredith <i>et al.</i> , "Treatment of metastatic prostate carcinoma with radiolabeled antibody CC49," <i>J. Nucl. Med.</i> , 35(6):1017-1022, 1994.
	C322	Namavari <i>et al.</i> , "Synthesis of 8-[18F]Fluoroguanin derivatives: in vivo probes for imaging gene expression with positron emission tomography," <i>Nucl. Med. Biol.</i> , 27:157-162, 2000.
	C323	Reed, "Apoptosis-targeted therapies for cancer," <i>Cancer Cell</i> , 3:17-22, 2003.
	C324	Smalley <i>et al.</i> , "Localization of fluorescent compounds in the firefly light organ," <i>J. Histochem. Cytochem.</i> , 28(4):323-329, 1980.
	C325	Smith <i>et al.</i> , "Prognostic significance of vascular endothelial growth factor protein levels in oral and oropharyngeal squamous cell carcinoma," <i>J. Clin. Oncol.</i> , 18(10):2046-2052, 2000.

23416404.1

EXAMINER:

DATE CONSIDERED: 5/31/05

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.



Form PTO-1449 (modified)		Atty. Docket No. UTSC:664USC1	Serial No. 10/672,763
List of Patents and Publications for Applicant's  INFORMATION DISCLOSURE STATEMENT  (Use several sheets if necessary)		Applicants David Yang <i>et al.</i>	
		Filing Date: September 26, 2003	Group: Unknown 1618
U.S. Patent Documents See Page 1	Foreign Patent Documents See Page 1	Other Art See Page 1	

### Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C326	Taggart <i>et al.</i> , <i>Human Mutation</i> , 13(3):210-220, 1999.
	C327	Tjuvajev <i>et al.</i> , "Comparison of radiolabeled nucleoside probes (FIAU, FHGB, and FHPG) for PET imaging of HSV1-tk gene expression," <i>J. Nucl. Med.</i> , 43:1072-1083, 2002.
	C328	Tschopp <i>et al.</i> , "Apoptosis: silencing the death receptors," <i>Curr. Biol.</i> , 9:R381-R384, 1999.
	C329	Ugurel <i>et al.</i> , "Increased serum concentration of angiogenic factors in malignant melanoma patients correlates with tumor progression and survival," <i>J. Clin. Oncol.</i> , 19(2):577-583, 2001.
	C330	Yaghoubi <i>et al.</i> , "Human pharmacokinetic and dosimetry studies of {18F}FHGB: a reporter probe for imaging herpes simplex virus type-1 thymidine kinase reporter gene expression," <i>J. Nucl. Med.</i> , 42:1225-1234, 2001.
	C331	Ye <i>et al.</i> , "TRAF family proteins interact with the common neurotrophin receptor and modulate apoptosis induction," <i>J. Biol. Chem.</i> , 274(42):30202-30208, 1999.
	C332	Yeh <i>et al.</i> , "Fluorine-18 fluoromisonidazole tumour to muscle retention ratio for the detection of hypoxia in nasopharyngeal carcinoma," <i>Eur. J. Nucl. Med.</i> , 23(10):1378-1383, 1996.
	C333	Yen <i>et al.</i> , "A comparative study of evaluating renal scars by 99mTc-DSMA planar and SPECT renal scans, intravenous urography, and ultrasonography," <i>Ann. Nucl. Med.</i> , 8(2):147-152, 1994.
	C334	Yen <i>et al.</i> , "Technetium-99m-DMSA renal SPECT in diagnosing and monitoring pediatric acute pyelonephritis," <i>J. Nucl. Med.</i> , 37(8):1349-1353, 1996.
	C335	Yen <i>et al.</i> , "The role of technetium-99m sestamibi whole-body scans in diagnosing metastatic Hurtle cell carcinoma of the thyroid gland after total thyroidectomy: a comparison with iodine-131 and thallium-201 whole-body scans," <i>Eur. J. Nucl. Med.</i> , 21(9):980-983, 1994.
	C336	Co-Pending U.S. Patent Application 09/599,152 filed 6/21/00.
	C337	Co-Pending U.S. Patent Application 10/672,142 filed 9/26/03.
	C338	Co-Pending U.S. Patent Application 10/703,405 filed 11/07/03.
	C339	Co-Pending U.S. Patent Application 10/732,919 filed 12/10/03.

25416404.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.